| Market Cap | 7.18M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -43.38M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -45.00% |
| Sales | 453k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -69.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -98.00% |
| Recommedations | - | Quick Ratio | 0.00 | Shares Outstanding | 8.95M | 52W Low Chg | 12.00% |
| Insider Own | 35.97% | ROA | -61.53% | Shares Float | 4.46M | Beta | 1.76 |
| Inst Own | 4.16% | ROE | -1,754.50% | Shares Shorted/Prior | 210.04K/64.48K | Price | 0.15 |
| Gross Margin | 8.61% | Profit Margin | - | Avg. Volume | 2,926,850 | Target Price | - |
| Oper. Margin | -35,070.00% | Earnings Date | Apr 25 | Volume | 4,587,878 | Change | -14.34% |
FOXO Technologies Inc. engages in epigenetic biomarker underwriting technology and consumer engagement platform service business in the United States. It operates through two segments, FOXO Labs and FOXO Life. The company applies automated machine learning and artificial intelligence technologies to discover epigenetic biomarkers of human health, wellness, and aging. It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and FOXO Life, a sales and distribution platform focused on recruiting independent life insurance agents to sell life insurance with the Longevity Report. The company was founded in 2020 and is based in Minneapolis, Minnesota. FOXO Technologies Inc. is a subsidiary of FOXO Management LLC.
